At this time, the firm appears to be fairly valued. Gilead Sciences retains a regular Real Value of USD88.4 per share. The prevalent price of the firm is USD89.03. Our model calculates the value of Gilead Sciences from evaluating the firm fundamentals such as Return On Equity of 0.0056, current valuation of 129 B, and Return On Asset of 0.12 as well as inspecting its technical indicators and probability of bankruptcy.
Enterprise Value
129 B
Fairly Valued
Today 89.03
Please note that Gilead Sciences' price fluctuation is very steady at this time. Calculation of the real value of Gilead Sciences is based on 3 months time horizon. Increasing Gilead Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gilead stock is determined by what a typical buyer is willing to pay for full or partial control of Gilead Sciences. Since Gilead Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gilead Stock. However, Gilead Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical
Market 89.03
Real 88.4
Hype 89.23
Naive 84.77
The intrinsic value of Gilead Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gilead Sciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gilead Sciences helps investors to forecast how Gilead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gilead Sciences more accurately as focusing exclusively on Gilead Sciences' fundamentals will not take into account other important factors:
Gilead Sciences is presently projected to have takeover price of 129 B with market capitalization of 80.16 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Gilead Sciences fundamentals before making investing decisions based on enterprise value of the company
About 88.0% of the company shares are owned by institutions such as pension funds. The company had not issued any dividends in recent years. Based on the key indicators related to Gilead Sciences' liquidity, profitability, solvency, and operating efficiency, Gilead Sciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gilead Sciences has an asset utilization ratio of 41.65 percent. This implies that the Company is making USD0.42 for each dollar of assets. An increasing asset utilization means that Gilead Sciences is more efficient with each dollar of assets it utilizes for everyday operations.
Covid
Gilead Sciences Ownership Allocation
The market capitalization of Gilead Sciences is USD80.16 Billion. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Gilead Sciences Profitability Analysis
The company reported the revenue of 28.3 B. Net Income was 5.67 B with profit before overhead, payroll, taxes, and interest of 21.62 B.
About Gilead Sciences Valuation
The stock valuation mechanism determines Gilead Sciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Gilead Sciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Gilead Sciences. We calculate exposure to Gilead Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gilead Sciences's related companies.
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.